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New approach to develop ultra-high inhibitory drug using the power-function of 
the stoichiometry of the targeted nanomachine or biocomplex 
Dan Shu1,2,3, Fengmei Pi1,2,3, Chi Wang,2,4, Peng Zhang5 and Peixuan Guo1,2,3 * 
1Nanobiotechnology Center;  2Markey Cancer Center; 3Department of Pharmaceutical Sciences; 4Department of 
Biostatistics; University of Kentucky, Lexington, KY 40536, USA. 5Department of Surgery, University of Michigan 
Health System, Ann Arbor, MI-48109, USA. 
Abstract  
Aims: To find a method for developing potent drugs and to prove a 
hypothesis that drug inhibition potency depends on the stoichiometry 
of the targeted biocomplex. 
Methods: Phi29 DNA-packaging motor components were used to 
test this model for different stoichiometries. Virion assembly 
efficiency was assayed with Yang Hui's Triangle: ?? ? ??? ?
? ?????
?????
?
???
, where Z=stoichiometry, M=drugged subunits in 
each biocomplex,  p and q represent the fraction of drugged and 
non-drugged subunits in the population.  
Results: Inhibition efficiency follows a power function. When number 
of drugged subunits to block the function of the biocomplex K=1, the 
fraction of uninhibited biocomplex equals qz. Thus, stoichiometry has 
a multiplicative effect on inhibition. Targets with a thousand subunits 
showed the highest inhibition effect, followed by those with six and a 
single subunit. Complete inhibition of virus replication was found 
when Z = 6.  
Conclusion: Drug inhibition potency depends on the stoichiometry 
of the targeted components of the biocomplex or nano-machine. The 
inhibition effect follows a power function of the stoichiometry of the 
target biocomplex. 
Key words: Drug target, phi29 viral assembly, nanomotor, 
hexameric ATPase, bionanotechnology, nanobiotechnology, 
binomial distribution. 
Introduction 
Bacteria, viruses and cells contain biocomplexes and nanomachines 
composed of multiple subunits, such as biomotors [1,2,3,4], pumps 
[5], exosomes [6,7,8], valves [9,10,11], membrane pores 
[12,13,14,15], chaperonins[16], PCNA[17], ATPase [18,19], and 
tubes [20]. From a nanobiotechnological standpoint, these 
nanomachines can be used and converted to build sophisticated 
nano-devices including molecular sensors [21,22,23], patterned 
arrays, tuators [24], chips, microelectromechanical systems (MEMS) 
[25], molecular sorters [26], single pore DNA sequencing apparatus 
[12,13,21,27] or other revolutionary electronic and optical devices 
[28,29]. From a pharmaceutical standpoint, these multi-subunit 
biocomplexes or nanomachines have a potential for use as drug 
targets for therapeutics, as well as diagnostic applications such as 
pathogen detection, disease diagnosis, drug delivery, and treatment 
of diseases [22,23,30,31]. In the ASCE (Additional Strand Catalytic 
E) family including the AAA+ (ATPases Associated with diverse 
cellular Activities) and the FtsK-HerA superfamily in bacteria, viruses 
and cells, there are nanomotors that perform a wide range of 
functions [19,32,33] critical to chromosome segregation, bacterial 
binary fission, DNA/RNA and cell component transportation, 
membrane sorting, cellular reorganization, cell division, RNA 
transcription, as well as DNA replication, riding, repair, and 
recombination [1,34,35,36].  One of the directions of NIH Roadmap 
is to utilize these cellular nanomachines and biocomplexes for 
biomedical applications.    
Acquired drug resistance has become a major reason for failure 
treatment of a range of diseases, i.e., the chemotherapy for cancer, 
bacterial or viral infections.  Drug resistance of cancer has escalated 
and has partially contributed to the ~600,000 deaths in the USA in 
2012 [37]. HIV drug resistance has also become a major issue [38]. 
Many common pathogens have become resistant to current drug 
treatments, with new infectious diseases on the rise. The use of 
multidrug-resistant agents in biological weapons has created a 
previously unrealized challenge [39]. Thus, there is a need to 
develop new treatment strategies to combat drug resistance with 
new drug development methods. 
The first FDA-approved drug to treat multidrug-resistant tuberculosis, 
bedaquiline, follows a novel mechanism of inhibiting the bacterial 
ATP synthase of M. tuberculosis and other mycobacterial species, 
but had little activity against other bacteria [40]. To combat multidrug 
resistance in cancer, several approaches have been explored. One 
method is to target components that are highly important for the 
growth of the biological entity [41,42]. Another approach uses nano-
drug delivery carriers that are expected to enhance the binding 
efficiency of drugs to cancer cells[43,44,45,46], or cocktail therapy 
[47]. A third approach is to develop new combinational drugs with 
higher potency by acting on multiple targets [48,49]. This involves 
identifying multiple targets that when treated leads to a synergetic 
effect and optimizing the design of multi-target ligands[50].
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The approach of developing highly potent drugs through targeting of 
protein or RNA complexes with high stoichiometry has never  
been reported due to challenges in comparing efficacies of two drugs 
that can be confused by target essentiality with binding affinity. For 
instance, if two drugs target two stoichiometrically different targets, it  
becomes extremely difficult to prove whether the difference in drug 
efficiency is due to differences in their target binding affinity or 
essential level in the growth of the biological organism. In order to 
quantify effects from targeting biocomplexes of different 
stoichiometry, a well-studied multi-component system is required that 
allows empirical comparison of functional inhibition of individual 
components that are composed of different number of subunits.  
An example of one nanobiomachine is the dsDNA translocation 
motor, for which the ATPase protein is a pivotal component that 
assembles into a hexameric ring structure and translates the action 
of ATP binding and hydrolysis into mechanical motion to translocate 
DNA physically. The DNA packaging motor of bacteriophage phi29 
(Fig. 1A) [9,51,52,53] is composed of three essential co-axial rings: 
1) a dodecameric connector ring located at the vertex of the viral 
procapsid; 2) a hexameric packaging RNA (pRNA) ring [52] bound  
to the N-terminus of the connector [54], and 3) a hexameric ring of 
ATPase gp16 attached to the helical region of pRNA [10,19,55], 
powered through the hydrolysis of ATP resulting in DNA packaging. 
The use of Yang Hui's Triangle (Fig. 1B) or binomial distribution to 
determine the stoichiometry of the pRNA was first reported in 1997 
[56]. The use of similar mathematical methods to determine the 
stoichiometry of the protein subunits has also been reported more 
recently [51]. The copy number of ATP molecules required to 
package one full phi29 genomic dsDNA was predicted to be 10000 
[57]. It has recently been shown that this hexameric motor uses a 
revolution mechanism without rotation to translocate its genomic 
DNA [10,19,33,35,36,58,59].   
In this report, we hypothesize that the inhibitory efficiency of a drug is 
related to the stoichiometry of its targeted biocomplex; the higher the 
stoichiometry of the target complex, the more efficient the drug. This 
can lead to the development of potent therapeutics against high-
stoichiometric biomachines or biocomplexes as drug targets. We 
Figure 1: Stoichiometry of viral DNA packaging motor. (A) Illustration of Phi29 DNA packaging motor composed of 1 copy of genomic DNA that revolves 
through the channel wall (left panel), 6 copies of pRNA, 6 copies of ATPase gp16 and a connector channel. (B) Yang Hui Triangle. (C) Illustration of Z=6 and 
K=1, drug targeting anyone subunit of the complex will block its activity. (D) AFM image of hexameric re-engineered pRNA rings. (E). 3D structure of hexameric 
pRNA ring top view and side view from the  crystal structure of 3WJ (PDB ID: pRNA 3WJ, 4KZ2). (F) A crystal hexameric structure of AAA+ Protein CbbX 
withtop view and side view [85] (PDB ID: CbbX, 3Zuh, http://www.ebi.ac.uk/pdbe/emdb/) (G) Structure of the hexameric AAA+ molecular machine ClpC with 
adaptor protein MecA. [86] (PDB ID: MecA-ClpC, 3PXG).  
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proved this hypothesis by using a mutant subunit as the drugged 
inactive target to calculate the theoretical inhibition efficiency via 
binomial distribution, and compared with experimental data from a 
defined in vitro viral assembly system. Since biomotors share certain 
common structures and operation mechanisms [1,36,59,60], the 
approach in drug development reported here should have general 
applications especially in developing new generations of drugs for 
combating the rising acquired drug resistance in viruses, bacteria, 
and cancers [38,61,62] .  
Materials and Methods 
Preparation of mutant genomic dsDNA  
Phi29 genomic DNA-gp3 was purified from B. subtilis SpoA12 cells 
by CsCl gradient ultracentrifugation as described previously [63]. 
Mutant dsDNA was prepared by digesting the phi29 genomic dsDNA 
with EcoR1 restriction enzyme in fast digest buffer (Fermentas) at 37 
°C for 1 hour followed by ethanol precipitation. The mutant DNA was 
tested by 1% agarose gel electrophoresis, stained by ethidium 
bromide (Sigma) and imaged by Typhoon (GE). 
Preparation of mutant pRNA 
Wild-type phi29 pRNA and inactive mutant as drugged pRNA were 
prepared by in vitro transcription. In the inactive mutant pRNA, the 
first four bases “UUCA” located at the 5’ end were mutated to 
“GGGG”. BglII digested plasmid pRT71 was used as DNA template 
[64] in the PCR reaction for both RNAs. Oligonucleotide 5’-TAA TAC 
GAC TCA CTA TAG GGG TGG TAC-3’ and 5’-TTA TCA AAG TAG 
CGT GCA C-3’ were used as primers for mutant pRNA. RNAs were 
then transcribed by T7 RNA polymerase using double-stranded DNA 
generated from PCR, as described before [65]. The RNA from in 
vitro transcription was further purified by 8 M urea 8% 
polyacrylamide gel electrophoresis as described previously [64].  
Preparation of mutant ATPase gp16 
The purification of wild-type gp16 has been described previously 
[63]. The walker B mutant gp16 was constructed by introducing 
mutations in the gp16 gene. The amino acid residues D255 and 
E256 in walker B motif of gp16 were mutated to E255 and D256, 
respectively. The mutation was introduced with the Stratagene Quick 
Change site-directed mutagenesis kit using appropriate primers. The 
expression and purification of protein were carried out followed a 
published procedure [51]. 
Antisense oligonucleotides 
Antisense oligonucleotides P3 and P15 were designed to be 
reversely complementary to different regions on the pRNA molecule 
and chemically synthesized by IDT. P3 oligo (5’-
TTGCCATGATTGACAAC-3') targets the region of 83-99 nucleotides 
at the 3’end of pRNA, P15 oligo (5’-AAGTACCGTACCATTGA-3') 
targets the region of 1-17 nucleotides at the 5’end of pRNA. P8 oligo 
(5'-TAATACGACTCACTATAGGGGTGGTAC-3') was designed as a 
non-targeting control in the test. 1 μl of individual oligos at 100 μM 
were mixed with 1 μl of pRNA at 4 μM and dialyzed on a 0.025 μm 
mixed cellulose esters VSWP filter membrane (Millipore Corp) 
against TBE buffer (89 mM Tris-HCl, pH 8.3, 89 mM boric acid, 2.5 
mM EDTA) at room temperature for 15 min. The purified RNA 
complex was used for in vitro phi29 assembly assay. 
In vitro phi29 assembly assay 
Purified components were subjected to in vitro viral assembly assay 
as described previously [66]. Briefly, 10 μg of purified procapsids 
were mixed with 100 ng of pRNA in 5 μl of reaction buffer (10 mM 
ATP, 6 mM 2-mercaptoethanol, and 3 mM spermidine in TMS buffer) 
at room temperature for 30 min. Purified DNA-gp3 and gp16 were 
then added and the reaction mixture was incubated at room 
temperature for one hour to initiate DNA packaging. Finally, the DNA 
filled procapsids were incubated with 10 μl of gp8.5-9 extract from 
E.coli containing plasmid pARgp8.5-9 and 20 μl of gp11-14 extract 
from E.coli to complete the infectious phage assembly. 
The newly assembled infectious viruses were plated with inoculated 
B. subtilis bacteria Su+44 cells onto a half LB plate covered with top 
agar. After 12 hour incubation at 37 °C, the viral assembly efficiency 
(plaque-forming unit, PFU) was calculated by counting the formed 
plaque numbers. Mixing different ratios of mutant with wild-type 
components, while keeping all other components the same, the viral 
assembly efficiency (PFU) versus ratio of mutant components gave 
an empirical curve for vial assembly inhibition assay, and it was 
compared with theoretical curves from the binomial distribution 
equation. 
In vivo viral assembly assay 
Plasmid pRBwtRNA containing the pRNA coding sequence under T7 
promoter was constructed by ligating the fragment coding pRNA 
sequence and T7 promoter into pRB381-L550 vector (modified and 
kindly provided by M. Wang and H. Zalkin) following a previously 
described method [67]. Plasmid pRBmutRNA contained mutant 
pRNA under its natural promoter PE1 sequence, and the mutation 
was changing sequence 5’UUGA-3’ at its 3’end to 5’GGGG-3’. The 
DNA fragments coding mutant pRNA sequence and PE1 sequence 
were prepared by PCR as described previously[67]; and digested 
with HindIII-BglII restriction enzyme. The mutant pRNA sequence 
coding fragment was further ligated with a 6.0kb fragment from 
pRB381-L550 that was digested with HindIII and partially digested 
with BglII.  
The plasmids pRBmutRNA, pRBwtRNA, and pRB381-L550 were 
transformed into B. subtilis cells following methods described 
previously [67]. The B. subtilis cells harboring transformed plasmids 
were incubated in 416 medium with 10 mg/ml of neomycin for 3 
hours at 37 °C and then plated onto LB-neomycin (10 mg/ml) plates 
for plaque formation analysis. 
Results  
The Definition of "Stoichiometry" 
The definition of the stoichiometry in this report is different from 
conventional definition of stoichiometry used to evaluate drug 
efficiency. Conventionally the concept of stoichiometry refers to the 
number of a drug binding to each target molecule, which is also 
known as Bmax. In this study the definition of stoichiometry refers to 
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the copy number of subunit within a biocomplex or the nanomachine 
that serves as drug target.  
The definition of "K value", and  K = 1 is one key for ultra-high 
inhibition efficacy  
 Suppose a biocomplex drug target contains Z copies of subunits, 
then K  is the copy number (K ≤ ?) of drugged subunits required to 
inhibit the function of the complex or the nanomachine. As an 
analogy to the difference between the parallel circuit and the serial 
circuit, when the Christmas lights are arranged in a parallel circuit, 
any light bulbs that are burnt out will not affect other bulbs.  But in a 
serial circuit, any one light bulb that is broken will stop the entire 
lighting system, which is K=1. Thus, the K value is the key to the 
probability of inactive nanomachines or biocomplexes by 
combination and permutation of all subunits. K equals 1 is critical for 
such ultra-high inhibition effect. The foundation of the approach in 
this report is the difference in probability of inhibited biocomplexes in 
systems of different K values with combination and permutation 
algorithms. Biological systems display complicated reactions. Many 
reactions involve multiple subunits to work cooperatively sequentially 
or processively to accomplish one essential biological function 
[33,68,69,70,71,72,73,74,75]. Single assembly pathways have been 
reported in the viral assembly system [76,77]. In most cases of the 
sequential, cooperative, and precessive action, inactivation of any 
one, not necessary all, of the subunits will result in inhibition of its 
function, thus K =1. Drug synergism was utilized in multi-target drug 
therapy;  in short, a drug combination can simultaneously act on 
multiple targets in disease networks to produce a synergistic effect 
[50,78]. However, our design reported here is unique from the 
conventional synergistic approach. We suggest that using multi-
subunit biocomplexes as drug target could lead to development of 
ultra-high potent drugs.  In a conventional six-component system, for 
example one drug is designed to  target component #3 to stop the 
entire system, since the drug can only target component #3, the 
condition fits the model of Z=1 and K=1. Thus, the inhibition 
efficiency and substrate targeting efficiency (p) of drug will be in 
linear relationship. However, in the system in this report, the entire 
system will be blocked when drug targets any subunit of a hexamer, 
which is Z=6 and K=1. Thus the probability of remaining undrugged 
targets will be q6, where q represents the fraction of untargeted 
hexamer subunits; in other words, the drug inhibition efficiency will 
be 1-q6 , which increases following a power function compared to the 
linear for conventional mono-subunit approaches. 
Assuming that at least K copies of drugged subunits were needed to 
deactivate the nanomachine or biocomplex, the probability of 
functional biocomplexes in the presence of various ratios of inhibited 
and wild-type subunits could be predicted from equation 2. When 
K=1, it implies that drug binding to one subunit will inactivate the 
subunit, and one drugged subunit per multi-subunit complex is 
sufficient to inhibit the overall function of the complex. The inhibition 
efficiency by drugs targeting multi-subunit biocomplexes with 
stoichiometry of Z will equal?? ? ??, as shown in table 1. An example 
for such a probability calculation when Z = 6 and K = 1 is as follows: 
since it was assumed that 6 (Z = 6) copies of subunits per element 
were required for function and one drugged subunit (K = 1) was 
sufficient to block its activity, all elements possessing 1 to 5 copies of 
drugged subunits would be non-functional (Fig. 1C). Only those 
complexes possessing 6 copies of normal subunits will be functional. 
The chance for a complex containing 6 copies of unaffected subunits 
in a population is q6 and the inhibition efficiency will be ? ? ??.  
Rationale behind selection of multi-subunit biocomplexes as 
efficient drug targets  
Mechanisms for drug inhibition of organism growth are to block or 
stop an essential biological element from functioning. When a drug is 
designed to target the subunit of a complex with targeting efficiency 
p, a fraction of subunits will not interact with the drug (a percentile 
given as q, p+q=1) and will remain active and exert their function 
properly. Some biological elements are monomers containing only 
one subunit, while other biological elements, such as the bio-motors 
of hexameric AAA+ family, consist of multiple-subunits [19,34]. 
Conventional drugs are designed to inhibit pathogenesis through 
targeting of a single subunit molecule, such as an enzyme or a 
structural protein of a virus. In this situation, the inhibition efficiency 
is proportional to the substrate targeting efficiency p and the effect is 
proportional to the first order of p.  As described above, in most 
cases of sequential action or cooperatives in multiple subunit 
complexes, inactivation of one, not all, of the subunits will result in 
inhibition of its function. Thus, if complexes containing Z copies of 
subunits exercise their function in a sequential and cooperative way, 
then K=1, and the fraction of the uninhibited active biocomplex will 
be qz, a higher order with regards to the stoichiometry.  The inhibition 
proportion will equal ? ? ????   
In this investigation, a well-defined in vitro phi29 viral assembly 
system was used to represent a multi-subunit nano-machine target, 
with the mutant component representing a target component that 
have been inactivated by an effective drug. Then, the inhibition 
efficiencies by targeting different elements of the phi29 DNA 
packaging motor with different stoichiometry were compared. The 
viral assembly competition assays combined with binomial 
distribution analysis illustrated the concept that drug targeting 
functional biological complexes of a higher-stoichiometry has a 
higher efficiency than drug acting on a single subunit target. 
When the target element is a monomer containing only one subunit, 
the inhibition efficiency can be calculated through a binomial 
distribution (equation 1), where p and q are the fractions of drugged 
(substrate targeting efficiency) and undrugged (normal active 
elements) subunits, respectively (p + q = 1). 
Z=1, 
K=1
Z=2, 
K=1
Z=3, 
K=1
Z=4, 
K=1
Z=5, 
K=1
Z=6, 
K=1
Z=7, 
K=1
Z=8, 
K=1
Z=9, 
K=1
Z=10, 
K=1
Z=11, 
K=1
Z=12, 
K=1
0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.1 0.90 0.81 0.73 0.66 0.59 0.53 0.48 0.43 0.39 0.35 0.31 0.28
0.2 0.80 0.64 0.51 0.41 0.33 0.26 0.21 0.17 0.13 0.11 0.09 0.07
0.3 0.70 0.49 0.34 0.24 0.17 0.12 0.08 0.06 0.04 0.03 0.02 0.01
0.4 0.60 0.36 0.22 0.13 0.08 0.05 0.03 0.02 0.01 0.01 0.00 0.00
0.5 0.50 0.25 0.13 0.06 0.03 0.02 0.01 0.00 0.00 0.00 0.00 0.00
0.6 0.40 0.16 0.06 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.7 0.30 0.09 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.8 0.20 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.9 0.10 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inhibited 
subunit 
(p)
Porbability of the multisubunit complex is active w ith:
Table1. Predicted inhibition efficiency of drugs targeting biocomplex, K=1
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 X = (p + q) 1        (1) 
However, when the target element contains multiple subunits, a high 
order binomial distribution (equation 2) is applied to calculate the 
drug inhibition effect by finding the ratio of resulted active and 
inactive complexes, where Z represents the total number of subunits 
(the stoichiometry) in one biocomplex and M represents the number 
of drugged subunits in one biocomplex.  
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For example, if Z is 3, the probability of all combinations of drugged 
subunits (M) and undrugged subunits (N; M + N = Z) in a given 
biocomplex entity can be determined by the expansion of equation 2: 
?? ? ??? ? ?? ? ???? ? ???? ? ?? ? ? . That is, the probability of a 
complex element possessing three copies of drugged subunits in the 
population is?? , two copies of drugged and one copy of undrugged 
or wild-type subunit is ???? , one copy of drugged and two copies of 
undrugged subunits is ????, and three copies of undrugged subunits 
is ?? . Assuming there were 70% (p=0.7) of subunits inactivated by 
bound drugs, and 30% (q=0.3) unaffected subunits in the population, 
then the percentage of elements possessing at least two copies of 
normal subunits would be the sum of those possessing one copy of 
drugged and two copies of undrugged wild-type subunits,?????, and 
those possessing three copies of native subunits is ??. That is 3pq
2
 
+ q
3
 = 3(0.7)(0.3)
2
 + (0.3)
3
 = 0.216 = 21.6% . In another example, if 
one complex contains 6 subunits, and 5 out of the 6 subunits need to 
remain uninhibited in order to be biologically functional, the active 
complex ratio in the population will be the sum of: 1) the probability 
of each element containing 5 undrugged subunits, and 2) the 
probability of each element containing 6 undrugged subunits.  
The probability X in the population displaying a certain combination 
of undrugged versus drugged subunits can be predicted by a 
binomial distribution, as shown in equation 2. Table 2 shows the 
probability of a given element with M drugged and N undrugged 
subunits at increasing percentages of drugged subunits in the 
population, considering that the total subunits in one element (Z) is 3 
or 12.  The formula, ??
????
????   (from equation 2) was used to 
calculate each combination probability value, the coefficient 
!!
!
NM
Z  in 
this equation can also be calculated using Yang Hui Triangle, which 
is also called Pascal's Triangle, or binomial distribution (Fig. 1B)[79].  
In vitro virus assembly system used for testing the hypothesis 
The highly sensitive in vitro phi29 assembly system was used to 
determine the inhibition efficiency of drugs targeting multi-subunit 
complexes [56,66,76,80]. Bacteriophage phi29 DNA packaging 
motor contains one copy of genomic dsDNA, 6 copies of packaging 
RNA, 6 copies of ATPase protein gp16 and more than 10000 copies 
of ATP. The stoichiometry of RNA in phi29 has been proven by 
extensive studies including single-molecule studies[81] AFM images 
(Fig.1D) [82,83], pRNA crystal structure determination (Fig.1E) [84], 
and mathematical studies [56]. The stoichiometry of gp16 in phi29 
has been proven by multiple approaches including native gel binding, 
capillary electrophoresis assays, Hill constant determination, and by 
titration of mutant subunits using binomial distribution [19,33]. Many 
other AAA+ superfamily members have been found to be hexamers 
as well [85,86,87,88,89,90,91], such as a red type rubisco activase 
AAA+ protein CbbX (Fig. 1F) [85], MecA-ClpC molecular machine 
(Fig. 1G)[86].  The copy number of ATP molecules was calculated 
based on the fact that 6 ATP molecules are required to package one 
pitch of dsDNA with 10.5 basepairs (bp) [92], thus 1 ATP is used to 
package 1.7 bp. The entire phi29 genome is composed of 19.4 kbp, 
thus, it is expected that more than 10000 ATP molecules are 
required to package the entire phi29 genome. The phi29 DNA nano-
motor which packages an entire genomic DNA into the procapsid 
can be treated as a disease model for drug inhibition efficiency 
analysis. 
In vitro testing of the hypothesis using DNA element with 
stoichiometry of 1 
Table 2. Probability of the complex containing M copies of drugged subunits and N copies of undrugged subunits
M =0, 
N=3
M =1, 
N=2
M =2, 
N=1
M =3, 
N=0
M =0, 
N=12
M =1, 
N=11
M =2, 
N=10
M =3, 
N=9
M =4, 
N=8
M =5, 
N=7
M =6,
N=6
M =7, 
N=5
M =8, 
N=4
M =9, 
N=3
M =10, 
N=2
M =11, 
N=1
M =12, 
N=0
0 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.1 0.73 0.24 0.03 0.00 0.28 0.38 0.23 0.09 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.2 0.51 0.38 0.10 0.01 0.07 0.21 0.28 0.24 0.13 0.05 0.02 0.00 0.00 0.00 0.00 0.00 0.00
0.3 0.34 0.44 0.19 0.03 0.01 0.07 0.17 0.24 0.23 0.16 0.08 0.03 0.01 0.00 0.00 0.00 0.00
0.4 0.22 0.43 0.29 0.06 0.00 0.02 0.06 0.14 0.21 0.23 0.18 0.10 0.04 0.01 0.00 0.00 0.00
0.5 0.13 0.38 0.38 0.13 0.00 0.00 0.02 0.05 0.12 0.19 0.23 0.19 0.12 0.05 0.02 0.00 0.00
0.6 0.06 0.29 0.43 0.22 0.00 0.00 0.00 0.01 0.04 0.10 0.18 0.23 0.21 0.14 0.06 0.02 0.00
0.7 0.03 0.19 0.44 0.34 0.00 0.00 0.00 0.00 0.01 0.03 0.08 0.16 0.23 0.24 0.17 0.07 0.01
0.8 0.01 0.10 0.38 0.51 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.05 0.13 0.24 0.28 0.21 0.07
0.9 0.00 0.03 0.24 0.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.09 0.23 0.38 0.28
1 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
Z=3 Z=12Inhibitied 
Subunits 
(p )
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Figure 3: Theoretical plot (K=1 to 6) and empirical data to illustrate inhibition efficiency with drug targeting pRNA (Z=6). (A) The sequence and secondary 
structure of wild-type pRNA of phi29 DNA packaging motor (upper panel) and inactive mutant pRNA with 4 bases mutation at 5’end of the DNA translocation 
domain serving as a model of drugged inactive pRNA(lower panel). (B) Fitting the phage assembly inhibition result by inactive mutant pRNA with the theoretical 
plots derived from Equation 2 matched with Z=6 and K=1. (C) Comparing the viral assembly inhibition effect by drugged pRNA at different concentration with 
the undrugged pRNA with same dilution factor.  
The inhibition efficiency of drugs targeting a single subunit substrate 
was tested by in vitro phi29 assembly inhibition by mutating the 
genomic dsDNA (Fig. 2A). Various ratios of mutant DNA were mixed 
with wild-type DNA in in vitro viral assembly assays. The empirical 
curve of viral assembly efficiency against drugged mutant DNA ratio 
fits well with the theoretical curve from binomial distribution for Z = 1 
and K = 1  (Fig. 2B). This suggests that when designing drug 
targeting the genomic DNA in phi29 nanomotor, it is expected to be a 
first order inhibition response. Comparing the in vitro phi29 assembly 
inhibition, by adding drugged mutant DNA, with simply diluting wild-
type DNA concentration as a control, revealed that the drugged 
mutant DNA didn’t cause much difference (Fig. 2C). The results 
showed that the inhibition effect of drugs targeting the substrate with 
stoichiometry of 1 is minimal.  
In vitro testing of the hypothesis using RNA elements with 
stoichiometry of 6 
The pRNA of phi29 contains two domains; a head-loop domain 
essential for procapsid binding and a helix domain essential for DNA 
translocation (Fig. 3A, upper panel) [30,93,94]. The right-hand loop 
and left-hand loop of two pairing pRNA molecules can interact with 
each other by complementary base pairing. Extensive studies have 
led to the conclusion that 6 copies of pRNA form a hexameric ring 
which binds to the procapsid for virus activity [81,82,83,84]. Drugged 
mutant pRNA was constructed by mutating 4 nucleotide sequences 
at the 5’end region of pRNA (Fig. 3A, lower panel), which has been 
shown to compete with wild-type pRNA for procapsid binding, but 
was found to be deficient in allowing DNA packaging to occur [67]. 
The theoretical curves generated using the expansion of binomial 
distribution equation while total subunit number Z is 6 and varying K 
number from 1 to 6 are shown in Fig. 3B. Fitting the empirical data 
from phage assembly efficiency at different ratios of drugged mutant 
pRNAs into the theoretical curves, the empirical data fit into the 
theoretical curve of Z = 6 and K = 1. It suggested that the pRNA 
oligomer ring is composed of six copies of pRNA subunits and one 
subunit of the pRNA multimer blockage is sufficient to block the 
phage assembly activity. Comparing the empirical curve for viral 
Figure 2: Theoretical plot (with variable Z) and empirical data to illustrate inhibition efficiency with drug targeting to genomic DNA ( Z-1). (A) Gel showing the 
phi29 genome DNA treated with endonuclease EcoR1. (B) Plot of  virion assembly derived from binomial distribution equation 2, which showed that the DNA 
has stoichiometry of 1. (C) Viral assembly inhibition effect of mutant DNA as model of drugged component with Z=1, showing the linear relationship to p with 
low slope.  
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assembly efficiency against different ratios of drugged mutant 
pRNAs with the wild-type pRNA concentration dilution control, 
addition of drugged mutant pRNA showed a much stronger inhibition 
effect (Fig.3C).  
To further prove the concept that drugs targeting biocomplex with 
high stoichiometry causes stronger inhibition effect, antisense 
oligonucleotides which can bind to pRNA molecules were designed 
as mock drugs in the viral assembly assay. The oligonucleotides 
P15, and P3 were designed to target the 5'-end and 3’-end regions 
on pRNA, respectively. It was confirmed that the antisense 
oligonucleotides can be hybridized to pRNA by gel shift assay (data 
not shown). When mixing the antisense oligonucleotides with wild-
type pRNA for in vitro phi29 assembly assay, complete inhibition 
effects were shown by antisense oligonucleotides P15, and P3, but 
not with the non-targeting control oligonucleotide P8[95]. By mixing 
the non-targeting oligo P8 with pRNA, it generated plaques with 
4.4×106 PFU on the plate.  
In vivo testing of the hypothesis using RNA elements with 
stoichiometry of 6 
Formation of the hexameric ring of pRNA in the phi29 dsDNA 
packaging motor has been discovered through biochemical and 
structural studies [52,81,84,96,97,98,99,100,101,102,103] and 
activity assays [94,104]. The observed high inhibition efficiency by 
drugged mutant pRNA on phi29 assembly in vitro was striking 
[67,105]. To test whether such a high level of inhibition was 
attainable in vivo, pRBmutRNA plasmid expressing a pRNA with 4-
base mutation at the 3' end (Fig. 4A) was transformed into B. subtilis 
DE1 cells. Plasmid pRBwtRNA contained the pRNA coding 
sequence but do not express pRNA in B. subtilis DE1 cells, and 
vector pRB381-L550 was introduced as well as a negative control. 
The results showed that only cells harboring pRBmutRNA plasmid 
were completely resistant to plaque formation by wild-type phi29 
virus infection. Control cells, including B. subtilis 12A cells alone, B. 
subtilis DE1 cells carrying vector pRB381-L550 alone, and cells 
carrying a wild-type pRNA coding sequence but no expression 
plasmid pRBwtRNA were all positive for plaque formation (Fig. 4B). 
The ability of mutant pRNAs generated in cells by plasmid 
pRBmutRNA completely inhibited plaque formation indicated that 
hexameric pRNA in DNA packaging nano-motor may be a potential 
target for developing potent antiviral agents [67].  
In vitro testing of the hypothesis using the ATPase with 
stoichiometry of 6 
Hexameric folding of ATPase gp16 protein in the phi29 dsDNA 
packaging motor has been discovered [1,19,33,35]. The hexameric 
gp16 protein complex functions as ATPase like many other AAA+ 
superfamily members. ATP binding to one subunit of gp16 stimulates 
the ATPase to change its conformation from having a lower affinity to 
one having a higher affinity for dsDNA.  
Determination of gp16 stoichiometry was carried out by in vitro 
phage assembly assay and based on the binomial distribution of 
wild-type and Walker B mutant gp16 [51]. Different ratios of drugged 
Walker B mutant gp16 were mixed with undrugged gp16 to test the 
inhibition efficiency of gp16 mutation on phi29 DNA packaging motor. 
Assuming K equals 1 and the total copy number of gp16 (Z) is 
between 1 and 12, twelve theoretical curves for the production of 
phi29 virion against the ratio of the Walker B mutant corresponding 
to the stoichiometry (Z) of 1 to 12 were generated according to 
equation 2. The empirical data nearly perfectly overlapped the 
theoretical curve of Z=6, K=1[51]. This data suggested that the 
ATPase gp16 components of phi29 DNA packaging motor have a 
stoichiometry of six, and only one copy of the drugged gp16 can 
block the phi29 motor function. Comparing the inhibition effect of 
adding mutant gp16 with wild-type gp16 at different concentrations, it 
showed that adding mutant gp16 had a much stronger inhibition 
effect than the wild-type gp16 concentration dilution control (Fig. 5A). 
Comparing the inhibition effect of mutation on hexameric gp16 to the 
effect of mutation on single subunit target DNA, the gp16 mutation 
displayed a much stronger inhibition effect on virus assembly than 
the same ratio of DNA mutation, indicating the hexameric ATPase 
protein complex of virus assembly system should also be an efficient 
target for generating new anti-virus drugs with high potency. 
In vitro testing of the hypothesis using ATP with stoichiometry 
of more than 10000  
It has been reported that 6 ATP molecules are required to package 
one pitch of dsDNA with 10.5bp [90], thus 1 ATP is used to package 
1.7bp. As the entire phi29 genomic DNA has 19,000 base pairs, it is 
expected that more than 10000 ATP molecules are required to 
package the entire phi29 genome. Since concerning ATP, the 
functional unit displayed in Fig 5 is the viral production expressed as 
plaque-forming unit (PFU), so the production of one functional unit of 
PFU require 10000 ATP subunits to package one genomic DNA. 
Thus, the ATP in one phi29 nanomotor can be regarded as a 
stoichiometry of 10000. One non-hydrolysable ATP analogue γ-S-
ATP was treated as the drugged subunit that mixed with ATP at 
different ratios to test the inhibition effect of γ-S-ATP on phi29 
assembly efficiency. It was found that the inhibition curve of mutant 
ATP fits into the theoretical curve between Z=100, K=1 and Z=60, 
K=1 (Fig. 5B). The empirical ATP value derived from binomial 
distribution assay was different from real condition, since the 
binomial distribution equation was based on a condition that each 
subunits has the same binding affinity to the biocomplex in the 
targeted nanomotor, but due to the change of the  γ-S-ATP structure,  
it has a ATPase gp16 binding affinity lower than the normal ATP . 
Furthermore, the affinity difference in each subunit has a 
multiplicative effect in the nanomotor’s activity. Thus, there is a big 
Figure 4: Complete inhibition of viral assembly in vivo by mutant pRNA as a 
model of drugged complex (Z=6). (A) Inactivation of pRNA by introducing a 
4-nucleotide mutation at the 3’end. (B) Virion production by wild-type phi29 
infection using host cell B. subtilis harboring plasmid expressing mutant 
pRNA, wild-type pRNA, or plasmid only. 
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Figure 5: Comparision of inhibition efficiency using targets with different Z 
values. (A) Virion production inhibition effect of mutant gp16 (Z=6) at 
different concentration. (B) Inhibition efficiency by γ-s-ATP with ATP with 
high Z value. (C) Comparing the virus assembly inhibition effect by drugged 
components of DNA, pRNA, gp16 and ATP with stoichiometry of 1, 6, 6, 
10000 respectively. 
discrepancy between the curves with predicted Z value and the 
empirical Z value.   
Comparing virus assembly inhibition effect using different 
components, the γ-S-ATP showed a severe inhibition effect (Fig. 
5C). Adding 20% of gamma-s-ATP nearly completely inhibited the 
viral assembly. Comparing the inhibition effect targeting to ATP, 
pRNA, ATPase gp16, and DNA with stoichiometry of 10000, 6, 6, 
and 1, respectively, γ-S-ATP showed the strongest inhibition effect, 
while drugged mutant pRNA and mutant gp16 showed stronger 
inhibitory effect than mutant DNA (Fig.5C).  For example, adding 
20% mutant DNA caused 20% inhibition effect in viral assembly, 
while 20% of drugged mutant pRNA exerted 74%of inhibition effect 
on viral assembly and 20% of γ-S-ATP almost completely inhibited 
the viral assembly, indicating the higher the stoichiometry, the 
stronger the inhibition efficacy.  
Mathematical reasoning for the increase of inhibition efficacy  
Using a biological complex with higher stoichiometry as drug target 
will substantially reduce the proportion of non-inhibited complex. For 
K=1, the proportion of non-inhibited complex is qZ.  Table 3 
compares the proportion of non-inhibited complex from two 
populations with Z=6 and Z=1, respectively, with varied substrate 
targeting efficiency (p) when K =1. For example, when q=0.4, the 
proportion of non-inhibited complex is qZ=0.41=0.4 for Z=1, K=1. 
Therefore, only 1-0.4=60% of complex is inhibited. In contrast, for 
Z=6, K=1, the proportion of non-inhibited complex is qZ=0.46=0.0041. 
Therefore, 1-0.0041=99.59% of complex is inhibited. The ratio of the 
proportions of non-inhibited complex equals 0.0041/0.4 = 0.0102, 
indicating a 1/0.0102=98-fold decrease in the proportion of non-
inhibited complex. One more example is to use the drug targeting 
efficiency p = 0.9 to compare the inhibition efficiency between two 
groups with Z=6 and Z=1.  For Z=6, K=1, the proportion of inhibited 
complex is 1-qZ=1-0.16=0.999999. The proportion of non-inhibited 
complex is qZ=0.16=1E-6. For Z=1, K=1, the proportion of inhibited 
complex is 1-qZ=1-0.1=0.9. The proportion of non-inhibited complex 
is qZ=0.1.  The ratio of inhibition efficiency equals to 1E-6/0.1 = 1E-5, 
indicating a 10000-fold increase in inhibition efficiency (Table 3). 
The equation displays inhibitory effect with a power function of 
stoichiometry since when K=1, the percentage of uninhibited 
biocomplexes in the population equal to qz.  Since (P + q) = 1, thus q 
≤ 1, thus the larger the Z, the smaller the value of qz  That is to say, 
the higher the stoichiometry, the smaller number of the uninhibited 
background will display.  With the same substrate targeting efficacy, 
p, the inhibition efficiency is determined by z, the power of the 
equation component. The inhibitory effect is a power function 
concerning the stoichiometry. Thu, the higher the stoichiometry, the 
more efficient the inhibition comparing the drugs with same binding 
affinity. 
The half maximal inhibitory concentration (IC50) is commonly used to 
evaluate drug effect, which quantitatively indicates how much of a 
particular drug is needed to inhibit a given biological process by half. 
If we denote  as the percentage of drugged subunit needed to 
reach to 50% inhibition in the in vitro assay in the defined system, 
thus .Solving this equation, 
. Figure 6 shows the relationship between 
stoichiometry (Z) and drug targeting level p to reach the inhibition 
effect (IC), where p is the combined result of drug binding efficacy 
and drug concentration (dosage). When biocomplexes with 
stoichiometry of Z are used as drug targets, the dosage of drug or 
0 1 1 1 1
0.1 0.5314 0.9 0.5905 1.7
0.2 0.2621 0.8 0.3277 3.1
0.3 0.1176 0.7 0.1681 5.9
0.4 0.0467 0.6 0.0778 12.9
0.5 0.0156 0.5 0.0312 32
0.6 0.0041 0.4 0.0102 98
0.7 7.00E-04 0.3 0.0024 416
0.8 1.00E-04 0.2 0.0003 3333
0.9 1.00E-06 0.1 1.00E-05 10000
Table 3.  Comparison of proportion of non-inhibited complex betw een Z=6 
and Z=1 w hen K=1 but having equal drug targeting eff icacy 
Proportion of 
non-inhibited 
complex from 
the population 
with Z=6
Proportion of 
non-inhibited 
complex from 
the population 
with Z=1
Substrate 
targeting 
efficacy (p)
Ratio of the 
proportions of non-
inhibited complex 
from the two 
populations with 
Z=6  and  Z=1
Reduction (fo ld) in 
proportion of non-
inhibited complex 
comparing Z=6 
and Z=1
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the drug binding affinity presented by percentage of drugged 
subunits to reach IC50, IC25, or IC75 decreases. This clearly shows 
that as Z increases,  decreases (Fig. 6), and hence the drug 
is more potent. 
Discussion 
Aiming to find a method for developing drugs with ultra-high potency, 
we proposed that the inhibition efficiency of a given drug depends on 
stoichiometry of the biocomplex or bio-machine that was used as 
drug target. Here the definition of the stoichiometry is different from 
conventional definition of stoichiometry used to evaluate drug 
efficiency. Conventional thinking in drug development emphasizes 
stoichiometry which refers to the number of drug binding per target 
molecule, which is also known as Bmax. In this study the definition of 
stoichiometry refers to the copy number of subunit within a 
biocomplex that serves as drug target. We used phi29 viral 
components with a series of variable but known stoichiometry as 
mock drug targets to test the hypothesis. Both in vitro and in vivo 
virion assembly assays were employed to compare the inhibition 
efficiency targeting to components with different numbers of subunit 
stoichiometry. Viral inhibition efficiency was analyzed with Yang Hui's 
(Pascal’s) Triangle (or knowns as binomial distribution).  It was found 
that inhibition efficiency on virus replication correlates to the 
component stoichiometry of nano-machine as drug target. It 
displayed power law inhibitory effect since when K=1, the 
percentage of uninhibited biocomplexes in the population equal to 
qz.  With the same q and same K value, the inhibition efficiency is 
determined by z, the number of subunits within the biocomplex or the 
bio-machine as drug target.  Here z serves as the power in the 
equation, thus, the inhibitory effect is the power of the stoichiometry. 
Empirical data demonstrated that the target with thousand-subunits 
shows higher inhibition effect than the targets with six subunits, and 
in turn higher than the target with single subunit.  
In evaluation of drug effect, two parameters were commonly used. 
One is the half maximal inhibitory concentration (IC50), 
which quantitatively indicates how much of a particular drug is
needed to inhibit a given biological process by half. It is universally 
used as a measure of drug potency in pharmacological research. 
Another important parameter is the median lethal dose (LD50), which 
is also known as 50% of lethal concentration (LC50). LD50 is
frequently used to indicate a substance's acute toxicity. Obviously, 
the usefulness of a drug will dependent on the ratio of LD50 to IC50. 
The larger this ratio, the safer the drug. By ways of increasing the 
inhibition efficiency through targeting to the components with high 
stoichiometry, the IC50 of a drug will decrease. As a result, lower 
concentration of drug will be required for reaching a desired effect, 
resulting in a reduced toxicity of the drug.  
Most of current anti-cancer, anti-virus or anti-bacteria drugs target 
single enzymes or single proteins. Our data showed that drugs 
selected to target components, biocomplexes, or nano-machines 
with high copy numbers could lead to a much higher efficacy, and it 
could potentially solve the problem of low drug effect and multi-drug 
resistance.   
Conclusions 
Targeting the functional biological units with higher stoichiometries 
will have a higher efficiency of inhibition.  The inhibition effect is 
power, other than proportional, and the power, is the copy number of 
the drug-targeted element of the machine. The new theory 
developed herein suggests that potent drugs can be developed by 
targeting biocomplex with high stoichiometry, and a complete 
inhibition of virus, bacterium, or cancer is possible if a bio-machine 
with high stoichiometry is identified. Since bio-motors share certain 
common structure and operation mechanism in viruses, bacteria, 
and cells, this approach should have general application in drug 
development.   
Future Perspective 
Living systems contain many elegant arrays, motors and 
nanomachines that are multi-subunit complex. As reported here, 
these biocomplex with high copy number of components can serve 
as potent drug targets. For example, most members of the AAA+ 
family are hexamer [19,87,88,106,107,108]. However, these 
machines are common in living systems therefore the specificity and 
toxicity is an issue. For bacteria and virus, since our goal is to kill 
them nonexclusively, the specificity and toxicity is not an issue as 
long as the target biocomplex is not identical to that in human body.  
For cancers drugs, as long as a mutation is found in the multiple-
subunit biocomplex, it will be an ideal target for potent drug.  
Executive summary 
Aim 
• A method for developing potent drugs is sought.  
Hypothesis 
• Drug inhibition potency depends on the stoichiometry of the 
targeted biocomplex. 
Approach: 
Figure 6: Relationship between stoichiometry (Z) and drug targeting level (p, 
a combined result of drug binding efficacy and drug concentration) to reach 
the inhibition effect (IC).  
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• Phi29 viral components with variable stoichiometry were used 
as  model to prove the hypothesis 
• Virion assembly efficiency was assayed and analyzed with 
Yang Hui's Triangle: ?? ? ??? ?? ?????
??????
?
???
  
Results: 
• Inhibition efficiency displayed a power function of the 
stoichiometry of the target biocomplexes. The uninhibited 
biocomplex in population can equals to qz. Thus, the inhibitory 
effect is a power of the stoichiometry.  
• Targets with thousand-subunit showed higher inhibition effect than 
with six subunits, and in turn higher than target with single subunit.  
• A complete inhibition of virus, bacterium, or cancer was 
demonstrated when  targets with high stoichiometry was used as 
target. 
Conclusion 
• Drug inhibition potency depends on the stoichiometry of the 
targeted components of the biocomplex or nano-machine.  
• The inhibition effiect displayed a power funciton of the 
stoichiometry of the target biocomplex.  
• Since bio-motors share certain common structure and operation 
mechanism in viruses, bacteria, and cells, this approach should 
have general application in drug development.   
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